Autologous Tansfusion REquirements in Bone MArrow Harvest: The ATREMA Study
NCT04355130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7
Last updated 2023-02-16
Summary
Despite perioperative autologous donation (PAD) is widely used in healthy bone marrow (BM) donors to restrain the hemoglobin decrease after BM harvest, this practice is not supported by strong clinical evidences and has been abandoned by some transplant teams. The critical revision of data relative to 102 BM collection procedures performed at our center between 2014 and 2018 failed to demonstrate an advantage of 1 over 2 PAD. Conversely, clearly emerged that PAD reduce the hemoglobin levels at BM harvest. Basically, PAD practice consists in the transfer of RBCs from the subject into a plastic bag and back to the subject at BM harvesting. Indeed, the evidence of clinical benefits of PAD in BM donors are still elusive. For this reason, current procedures on unrelated donors recommend iron and vitamin supplementation before the BM harvest, but let the decision to perform or not PAD at collection centers. Detailed data on the safety and feasibility of BM harvest procedures in absence of PAD have been rarely reported. The investigators collect data on BM harvest in healthy donors who don't have PAD collected. The investigators expect that no allogeneic transfusions are required and that Hb levels after collection are similar to those recorded in the historical cohort gathered at the same center receiving 1 or 2 PAD.
Conditions
- Bone Marrow Donors
Interventions
- DIETARY_SUPPLEMENT
-
Iron, vitamin B12 and acid folic supplementation
Vitamin and iron supplementation is administered one-two weeks before donation, and consist of iron supplementation (i.v. infusion of 20 mg/Kg ferric carboxymaltose in saline 100 ml), s.c. injection of 1 mg of vitamin B12 and acid folic 5 mg/die per os until day +15 post BM donation. BM collection is carried out by the transplant team and a maximal dose of 20-22 ml/Kg of the donor body weight is collected under general anesthesia (induction with fentanyl 1-3 mcg/Kg, Propofol 2-3 mg/Kg, rocuronium 0,6 mg/Kg and mantenaince with sevoflurane 0,8 MAC). Noninvasive cardiac output, blood pressure and hemoglobin monitoring are carried out during the entire procedure and in in the recovery room using the ClearSight™ system (Edwards Clinical) and the Radical Pulse co oxymeter (Masimo). After discharge from the hospital, donors will be revaluated on day + 7 after BM collection, and blood tests will be repeated in outpatient setting.
Sponsors & Collaborators
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
lead OTHER
Principal Investigators
-
Luciana Teofili · Fondazione Policlinico Universitario A. Gemelli, IRCCS
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-03-20
- Primary Completion
- 2022-12-20
- Completion
- 2022-12-20
Countries
- Italy
Study Locations
More Related Trials
-
Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors
NCT01680055 ·Status: WITHDRAWN
-
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
NCT02338479 ·Status: UNKNOWN
-
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
NCT04528355 ·Status: RECRUITING
-
Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD
NCT00228631 ·Status: COMPLETED
-
ALLO-SCT in Elderly Patients With Hematological Disease
NCT04386928 ·Status: COMPLETED
-
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
NCT00001872 ·Status: COMPLETED
-
Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells
NCT00770523 ·Status: COMPLETED
-
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
NCT03904134 ·Status: COMPLETED ·Phase: NA
-
Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning
NCT00466674 ·Status: COMPLETED ·Phase: PHASE2
-
Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
NCT00450268 ·Status: UNKNOWN
-
α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD
NCT03188601 ·Status: COMPLETED
-
Role of Day +60 WT1 Assessment on Bone Marrow in Predicting Relapse and Mortality After Allogeneic Stem Cell Transplantation
NCT05755633 ·Status: COMPLETED
-
Maintaining a Higher Level of Haemoglobin: Effect on the White Cells After Bone Marrow Transplantation in Children.
NCT00937053 ·Status: TERMINATED ·Phase: PHASE2
-
Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03965429 ·Status: ACTIVE_NOT_RECRUITING
-
Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy
NCT06646640 ·Status: RECRUITING
-
Home Blood Transfusions
NCT07121140 ·Status: RECRUITING ·Phase: NA
-
Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study
NCT06277479 ·Status: COMPLETED
-
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03233659 ·Status: COMPLETED
-
Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202)
NCT01879072 ·Status: COMPLETED
-
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
NCT02623309 ·Status: COMPLETED ·Phase: PHASE3
-
Management Standard of Bone Marrow Infusion in Acute and Critical Patients
NCT04951596 ·Status: UNKNOWN
-
Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells
NCT07150468 ·Status: COMPLETED
-
Belgian Cross-sectional Allogeneic Transplant Survivor Study
NCT02312830 ·Status: ENROLLING_BY_INVITATION
-
Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
NCT06378060 ·Status: RECRUITING ·Phase: PHASE2
-
Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03357172 ·Status: RECRUITING ·Phase: NA